|
 |
|
POSTER PRESENTATIONS
SESSION II |
METHODS & CONCEPTS |
|
PMC1
|
SIMULATION
MODELING
OF
CARDIOVASCULAR
DISEASE:
IS
APPLYING
AVERAGE
LIFE
EXPECTANCY
TO ALL
SURVIVORS
DETAILED
ENOUGH?
|
|
|
Proskorovsky
I1,
Ishak KJ1,
Migliaccio-Walle
K2,
Caro JJ2 |
|
|
1Caro
Research
Institute,
Dorval,
QC,
Canada,
2Caro
Research
Institute,
Concord,
MA, USA
|
|
PMC2
|
EFFICIENT
DATA
MINING
AND
PROBABILISTIC
INFERENCE
WITH
P-COURSE:
A
BAYESIAN
METHOD
WITH
MULTILEVEL
PRIORS
FOR
MEDICAL
APPLICATIONS
|
|
|
Soini EJ1, Martikainen JA2, Lahtinen J3,
Myllymäki
P3,
Kontkanen
P3,
Valtonen
H4,
Ryynänen
OP5 |
|
|
1Department
of
Health
Policy
and
Management,
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
2Centre
for
Pharmaceutical
Policy
and
Economics
(CEPPE),
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
3Complex
Systems
Computation
Research
Group (CoSCo),
Helsinki
Institute
for
Information
Technology
(HIIT),
University
of
Helsinki,
Helsinki,
Finland,
4Department
of
Health
Policy
and
Management,
University
of
Kuopio,
Kuopio,
Finland,
5General
Practice,
Department
of
Public
Health
and
Clinical
Nutrition,
University
of
Kuopio,
Kuopio,
Finland
|
|
PMC3
|
WITHDRAWN |
|
|
|
|
PMC4
|
PRESENTING
IGNORANCE:
A
POSSIBILITY
INTERVAL
APPROACH
TO
DEPICT
HIGH-LEVEL
UNCERTAINTY
DUE TO
CENSORING
OR
NON-RESPONDENTS
|
|
|
Turunen
JH1,
Soini EJ2 |
|
|
1Equal
contribution
of both
authors.
Department
of
Social
Pharmacy,
University
of
Kuopio,
Kuopio,
Finland,
2Department
of
Social
Pharmacy,
Department
of
Health
Policy
and
Management,
University
of
Kuopio,
Kuopio,
Finland
|
|
 |
|
PMC5
|
INDIRECT
COSTS OF
COMMON
COLD IN
GERMANY
|
|
|
Hessel
FP,
Wasem J |
|
|
University
of
Duisburg-Essen,
Essen,
Germany
|
|
PMC6
|
IMPLEMENTING
NATURAL
HISTORY
STUDIES
IN
EURASIA:
THE
NIEMANN-PICK
EXPERIENCE
WITH
RAPIDLY
CHANGING
NATIONAL
REGULATIONS
|
|
|
Madison
M1, Finegan Y1, Sawyer R2, Koval S2,
Cox G2 |
|
|
1Abt
Associates
Inc,
Lexington,
MA, USA,
2Genzyme
Corporation,
Cambridge,
MA, USA
|
|
PMC7
|
Withdrawn |
|
PMC8
|
ECONOMIC
DECISION
MODELLING:
CALCULATION
OF TOTAL
NET
MONETARY
BENEFITS
OF
GUIDELINE
IMPLEMENTATION
INTO
CLINICAL
PRACTICE
|
|
|
Hoomans
T1, Ament A1, Evers S2, Severens JL3 |
|
|
1Maastricht
University,
Maastricht,
The
Netherlands,
2Maastricht
University,
Maastricht,
Nepal,
3Academic
Hospital
Maastricht,
Maastricht,
The
Netherlands
|
|
PMC9
|
A REVIEW
OF
FACTORS
AFFECTING
THERAPEUTIC
COMPLIANCE
|
|
|
Jin J,
Li SC |
|
|
National
University
of
Singapore,
Singapore,
Singapore
|
|
PMC10
|
ESTIMATING
UTILITY
VALUES
FOR
HEALTH
STATUS
USING
THE
SPANISH
VERSION
OF THE
SF-36.
IS IT
WORTHY
TO
CALCULATE
WEIGHT
VALUES
FOR
UTILITY
MEASURES?
|
|
|
Rebollo
P1, Morís J1, Prieto L2, Ortega F3,
Ortega T3 |
|
|
1BAP
Health
Outcomes,
Oviedo,
Spain,
2Madrid,
San
Agustín
de
Guadalíx,
Madrid,
Spain,
3Hospital
Universitario
Central
de
Asturias,
Oviedo,
Spain
|
|
PMC11
|
EFFECTIVE
USE OF
ELECTRONIC
DATA
CAPTURE
(EDC) TO
IMPROVE
THE
QUALITY
AND
EFFICIENCY
OF THE
ANALYSIS
OF
PATIENT
REPORTED
OUTCOMES
|
|
|
Ooms KL |
|
|
Statwood,
HITCHIN,
Hertfordshire,
UK
|
|
PMC12
|
REVIEW
ON THE
IMPACT
OF DOSE
FREQUENCY
ON
COMPLIANCE
AND
HEALTH
OUTCOMES
|
|
|
Shi L1,
Hodges M1,
Yurgin
NR2,
Secnik K2 |
|
|
1Tulane
University,
New
Orleans,
LA, USA,
2Eli
Lilly
and
Company,
Indianapolis,
IN, USA
|
|
PMC13
|
EMPIRICAL
RESEARCH
FOR
WILLINGNESSTO
PAYFOR
ONE QALY
GAIN
|
|
|
Ohkusa Y,
Sugawara
T |
|
|
National
Institute
of
Infectious
Diseases,
Shinjuku,
Tokyo,
Japan
|
|
PMC14
|
MEASURING
PATIENT-REPORTED
SIDE
EFFECTS
OF
DRUGS:
ITS
IMPORTANCE
AND
METHODOLOGICAL
CHALLENGES.
|
|
|
Foster
JM1, Van der Molen T1, Caeser M2,
Hannaford
P3 |
|
|
1University
of
Groningen,
Groningen,
The
Netherlands,
2ALTANA
Pharma
AG,
Konstanz,
Germany,
3University
of
Aberdeen,
Aberdeen,
Scotland,
UK
|
|
PMC15
|
HOSPITAL
PHARMACY
DRUG
DELIVERY
TIME: A
WORK
FLOW
MANAGEMENT
ISSUE
|
|
|
Pierce
CA1, Baker JJ2, McClard C2 |
|
|
1The
Resource
Group,
Richfield,
OH, USA,
2The
Resource
Group,
Pickton,
TX, USA
|
|
PMC16
|
PROPOSED
CHANGES
TO
PHYSICIAN
FEE
SCHEDULE:
2007
PRACTICE
EXPENSE
CONCEPTUAL
METHODOLOGY
|
|
|
Pierce
CA1, Baker JJ2 |
|
|
1The
Resource
Group,
Richfield,
OH, USA,
2The
Resource
Group,
Pickton,
TX, USA
|
|
PMC17
|
MONITORING
OF
PHARMACEUTICAL
COST OF
REIMBURSED
MEDICINES
BY
COMBINING
OFFICIAL
PHARMACY
INVOICE
DATA
WITH
COMMERCIAL
IMS
SALES
DATA.
|
|
|
Van
Wilder P,
Arickx
F, Van
Haeren
E,
Bormans
V |
|
|
RIZIV-INAMI,
Brussels,
Belgium
|
|
PMC18
|
USING
DISTANCE
LEARNING
TO
UNDERSTAND
DISCRETE
EVENT
SIMULATION
|
|
|
Hunting
B,
Moller
J, Caro
JJ |
|
|
Caro
Research
Institute,
Concord,
MA, USA
|
|
|
|
CANCER |
|
Clinical
Outcomes
Studies |
|
PCN1
|
THE
EPIDEMIOLOGIC,
HEALTH-RELATED
QUALITY
OF LIFE,
AND
ECONOMIC
BURDEN
OF
GASTROINTESTINAL
STROMAL
TUMORS
|
|
|
Reddy P1, Boci K2, Charbonneau C3, Pashos CL1 |
|
|
1Abt
Associates
Inc,
Lexington,
MA, USA,
2Abt
Associates
Inc,
Bethesda,
MD, USA,
3Pfizer,
New
York,
NY, USA
|
|
PCN2
|
INCIDENCE
AND
SURVIVAL
STUDY BY
STAGE
AND
ESTIMATED
PREVALENCE
OF RENAL
PARENCHYMA
CANCER
IN
FRANCE
|
|
|
Danzon A1,
Langlois
C1,
Grosclaude
P2,
Colonna
M3,
Delafosse
P3,
Martin E4,
Molinié
F5,
Tretarre
B6,
Velten M7,
Levrat F8 |
|
|
1Registre
des
tumeurs
du
Doubs,
Besançon,
France,
2Tarn
Cancer
registry,
Albi,
France,
3Isere
cancer
registry,
Meylan,
France,
4Somme
cancer
registry,
Amiens,
France,
5Loire
Atlantique
and
Vandée
cancer
redistry,
Nantes,
France,
6Herault
cancer
registry,
Montpelliers,
France,
7Universite
Louis
Pasteur,
strasbourg,
France,
8Pfizer,
Paris,
France
|
|
PCN3
|
EPIDEMIOLOGIC,
HUMANISTIC
AND
ECONOMIC
BURDEN
OF
PATIENTS
WITH
METASTATIC
RENAL
CELL
CARCINOMA
(MRCC)
|
|
|
Banks J1, Gupta K1, Balu S1, Chen E2,
Komatsuzaki
Y2,
Charbonneau
C3,
Pashos
CL1 |
|
|
1Abt
Associates
Inc,
Lexington,
MA, USA,
2Abt
Associates
Inc,
Bethesda,
MD, USA,
3Pfizer,
New
York,
NY, USA
|
|
|
|
Cost
Studies |
|
PCN4
|
A
COMPARATIVE
BUDGET
IMPACT
(BI)
ANALYSIS
OF
ARANESP®
(DARBEPOETIN
ALFA)
500µG
Q3W
VERSUS
OTHER
ERYTHROPOIESIS
STIMULATING
PROTEINS
(ESP) IN
CHEMOTHERAPY-INDUCED
ANEMIA
(CIA) IN
SPAIN
|
|
|
Pérez
Alcántara
F1,
Badia X2,
Arocho R3 |
|
|
1Health
Outcomes
Research,
Barcelona,
Barcelona,
Spain,
2Health
Outcomes
Research
Europe,
Barcelona,
Spain,
3Amgen
SA,
Barcelona,
Barcelona,
Spain
|
|
PCN5
|
HEXVIX
FLUORESCENCE
CYSTOSCOPY
FOR
SUPERFICIAL
BLADDER
CANCER
DIAGNOSIS:
ANALYSIS
OF
BUDGET
IMPACT
ON THE
SWEDISH
HEALTH
SERVICE
|
|
|
Thompson
G1,
Durrant
H2,
Kloster
Y3 |
|
|
1Bridgehead
International
Ltd,
Melton
Mowbray,
Leicestershire,
UK,
2Bridgehead
International
Limited,
Melton
Mowbray,
Leicestershire,
UK,
3Photocure
ASA,
Oslo,
Norway
|
|
PCN6
|
PRIMARY
PROPHYLAXIS
WITH
PEGFILGRASTIM
IS
COST-SAVING
COMPARED
WITH
FILGRASTIM
FOR
BREAST
CANCER
IN SPAIN
|
|
|
Mayordomo
JI1,
Lopez
Pousa A2,
Arocho R3,
Doan QV4,
Dubois R4,
Liu Z4 |
|
|
1Hospital
Clinico
Lozano
Blesa,
Zaragoza,
Spain,
2Hospital
Sant
Pau,
Barcelona,
Spain,
3Amgen
SA,
Barcelona,
Spain,
4Cerner
Health
Insights,
Beverly
Hills,
CA, USA
|
|
PCN7
|
IMPACT
OF
CHANGES
IN THE
FINANCING
OF THE
HEALTH
SERVICES
ON COSTS
STRUCTURE
ON THE
EXAMPLE
OF
CHEMOTHERAPY
OF
ADVANCED
OVARIAN
CANCER
|
|
PCN8
|
RISE OF
HEALTH
RESOURCE
UTILIZATION
AND
COSTS
FOR
SEQUENTIAL
DOCETAXEL
IN
NODE-POSITIVE
PRIMARY
BREAST
CANCER
IN
GERMAN
HOSPITALS
|
|
|
Ihbe-Heffinger
A1,
Wagenpfeil
S1,
Jacobs
VR1,
Gillessen
P1,
Bernard
R1,
Sattler
D2,
Kuhn W3 |
|
|
1Klinikum
rechts
der Isar
der
Technischen
Universität
München,
München,
Germany,
2Städtisches
Krankehaus
München-Harlaching,
München,
Germany,
3Universität
Bonn,
Bonn,
Germany
|
|
PCN9
|
ERLOTINIB
IN
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
IN
GERMANY
– A
COST-SAVING
SECOND-LINE
TREATMENT
OPTION?
|
|
|
Gabriel
A,
Pirk O,
Kotowa W |
|
|
Fricke &
Pirk
GmbH -
Member
of the
IMS
Health
Group,
Nuremberg,
Germany
|
|
PCN10
|
INCREMENTAL
COST-EFFECTIVENESS
RATIO OF
DARBEPOETIN
ALFA
(ARANESP®)
IN THE
TREATMENT
OF
CHEMOTHERAPY-INDUCED
ANEMIA
IN LUNG
CANCER
PATIENTS
|
|
|
Borget I1, Tilleul P2, Joly AC2, Chouaid C2 |
|
|
1Saint-Antoine
Hospital,
Paris,
France,
France,
2Saint-Antoine
Hospital,
Paris,
France
|
|
PCN11
|
PHARMACOECONOMIC
ANALYSES
OF
ERLOTINIB
COMPARED
WITH
BEST
SUPPORTIVE
CARE
(BSC)
FOR THE
TREATMENT
OF
RELAPSED
NON-SMALL
CELL
LUNG
CANCER
(NSCLC)
FROM THE
CANADIAN
PUBLIC
HEALTHCARE
PERSPECTIVE
|
|
|
Côté I1, Leighl NB2, Gyldmark M3, Maturi B1 |
|
|
1Hoffmann-La
Roche
Limited,
Mississauga,
ON,
Canada,
2Princess
Margaret
Hospital,
Toronto,
ON,
Canada,
3F
Hoffmann
La
Roche,
Basel,
Switzerland
|
|
PCN12
|
COST
EFFECTIVENESS
OF
ERLOTINIB
IN THE
TREATMENT
OF
ADVANCED
NON
SMALL
CELL
LUNG
CANCER
(NSCLC)
IN
POLAND
|
|
|
Orlewska
E1,
Szczesna
A2,
Gyldmark
M3,
Szkultecka-Debek
M4 |
|
|
1Centrum
Farmakoekonomiki,
Warsaw,
Poland,
2Regional
Lung
Diseases
Hospital,
Otwock,
Poland,
3F
Hoffmann
La
Roche,
Basel,
Switzerland,
4Roche
Polska
Sp. z
o.o,
Warsaw,
Poland
|
|
PCN13
|
COST-EFFECTIVENESS
OF
ADJUVANT
CAPECITABINE,
MAYO
CLINIC
AND DE
GRAMONT
REGIMENS
FOR
STAGE
III
COLON
CANCER
IN THE
FRENCH
SETTING
|
|
|
Tilleul
P1, Perrocheau G2, Lafuma A3, Roux E4 |
|
|
1Saint-Antoine
Hospital,
Paris,
France,
2Centre
Renée
Gauducheau,
Saint
Herblain,
France,
3Cemka-Eval,
Bourg-la-Reine,
France,
4Roche,
Neuilly
sur
Seine,
France
|
|
PCN14
|
COST-EFFECTIVENESS
STUDY OF
AN
ASPIRIN
CHEMOPREVENTION
ASSOCIATED
OR NOT
WITH A
COLONOSCOPIC
SURVEILLANCE
IN THE
COLORECTAL
CANCER
|
|
|
Francesconi
C1,
Benamouzig
R2,
Launois
R1 |
|
|
1REES,
Paris,
France,
2Hopital
Avicenne,
Bobigny,
France
|
|
PCN15
|
CAPECITABINE VS. BOLUS 5-FU/LV AS ADJUVANT THERAPY FOR PATIENTS WITH DUKES´ C COLON CANCER:
PHARMACOECONOMIC EVALUATION OF X-ACT TRIAL - DATA FROM CZECH PERSPECTIVE
|
|
|
Jiraskova
L1,
Dolezal
T2 |
|
|
1Faculty
of
Pharmacy,
Charles
University,
Hradec
Králové,
Czech
Republic,
2Charles
University,
Prague,
Czech
Republic
|
|
PCN16
|
COST-EFFECTIVENESS
OF
SORAFENIB
VERSUS
BEST
SUPPORTIVE
CARE IN
ADVANCED
RENAL
CELL
CARCINOMA
IN SPAIN
|
|
|
Maroto P1,
Villavicencio
H2,
Piñol C3,
Urruticoechea
L4 |
|
|
1Hospital
de la
Santa
Creu i
Sant
Pau,
Barcelona,
Spain,
2Fundació
Puigvert,
Barcelona,
Spain,
3Q.F.
Bayer,
S.A,
Barcelona,
Spain,
4Q.
F.
Bayer,
S.A,
Barcelona,
Spain
|
|
PCN17
|
COST
EFFECTIVENESS
OF
PRIMARY
PROPHYLAXIS
WITH
PEGFILGRASTIM
OR
FILGRASTIM
IN THE
MEDICAL
TREATMENT
OF
BREAST
CANCER
IN ITALY
|
|
|
Chiroli
S1, Dubois RW2, Doan QV2, Liu Z2,
Heissel
A3,
Palmeri
S4,
Danova M5 |
|
|
1Amgen,
Milan,
Italy,
2Cerner
Health
Insights,
Beverly
Hills,
CA, USA,
3Amgen
Europe,
Zug,
Switzerland,
4Policlinico
Universitario
P.
Giaccone,
Palermo,
Italy,
5Clinica
Medica,
Pavia,
Italy
|
|
PCN18
|
A
SENSITIVITY
ANALYSIS
OF THE
COST PER
QUALITY
ADJUSTED
LIFE
YEAR
(QALY)
OF
TRASTUZUMAB
IN THE
TREATMENT
OF EARLY
BREAST
CANCER
(EBC)
|
|
|
Geary U1, Lewis G2, Erny S3, Gyldmark M4,
Morlotti
L5,
Walzer S6 |
|
|
1Roche
Products
Limited,
Hertfordshire,
UK,
2Roche
Products
Limited,
Welwyn
Garden
City,
Herts,
UK,
3F.
Hoffmann-La
Roche
Pharmaceuticals
AG,
Basel,
Switzerland,
4F.
Hoffmann-La
Roche
Ltd,
Basel,
Switzerland,
5Analytica
Int,
Loerrach,
Germany,
6Analytica
International,
Loerrach,
Germany
|
|
PCN19
|
COST-EFFECTIVENESS
OF
CETUXIMAB
IN
COMBINATION
WITH
RADIOTHERAPY
VERSUS
RADIOTHERAPY
ALONE IN
THE
TREATMENT
OF
LOCALLY
ADVANCED
HEAD AND
NECK
CANCER
IN
SPAIN.
|
|
|
Brosa M1, Robinson P2, Brown B2 |
|
|
1Oblikue
Consulting,
Barcelona,
SC,
Spain,
2IMS
Health,
London,
UK
|
|
PCN20
|
COST-EFFECTIVENESS
ANALYSIS
OF
LETROZOLE
COMPARED
TO
TAMOXIFEN
FOR
TREATMENT
OF EARLY
BREAST
CANCER
IN THE
HUNGARIAN
HEALTH
CARE
SETTING
|
|
|
Kosa J |
|
|
Novartis
Hungary
Ltd,
Budapest,
Pest,
Hungary
|
|
PCN21
|
RETROSPECTIVE
COMPARATIVE
PHARMACOECONOMIC
ANALYSIS
OF
VARIOUS
TREATMENT
SCHEMES
IN
PATIENTS
WITH
ADVANCED
HODGKIN'S
DISEASE
|
|
|
Tolkushin
AG1,
Yagudina
RI1,
Moiseeva
TN2,
Khabriev
RU1 |
|
|
1Moscow
Medical
Academy,
Moscow,
Russia,
2Hematological
Scientific
Center
of the
Russian
Academy
of
Medical
Sciences,
Moscow,
Russia
|
|
PCN22
|
COST-EFFECTIVENESS
(CE) OF
THE
PREVENTION
OF ORAL
MUCOSITIS
(OM)
WITH
KEPIVANCE®
(PALIFERMIN)
IN
PATIENTS
UNDERGOING
MYELOABLATIVE
THERAPY
WITH
AUTOLOGOUS
STEM
CELL
TRANSPLANTATION
(ASCT)
IN
SPAIN.
|
|
|
Brosa M1, Arocho R2 |
|
|
1Oblikue
Consulting,
Barcelona,
SC,
Spain,
2Amgen
SA,
Barcelona,
Spain
|
|
PCN23
|
ADDING
RITUXIMAB
TO
STANDARD
CHEMOTHERAPY
IS COST
NEUTRAL
AND
CLINICALLY
SUPERIOR
IN
ADVANCED
STAGE
NON-HODGKIN'S
LYMPHOMA
(NHL)
|
|
|
Hieke K1, Herold M2 |
|
|
1NEOS
Health,
Binningen,
Switzerland,
2HELIOS
Klinikum
Erfurt,
Erfurt,
Germany
|
|
PCN24
|
PEGFILGRASTIM
PRIMARY
PROPHYLAXIS
IS MORE
COST-EFFECTIVE
THAN
FILGRASTIM
IN WOMEN
WITH
BREAST
CANCER
RECEIVING
CHEMOTHERAPY
IN
FRANCE
|
|
|
Bogillot
O1,
Dubois R2,
Doan QV2,
Liu Z2,
Heissel
A3,
Di Palma
M4 |
|
|
1Amgen
S.A,
Paris,
France,
2Cerner
Health
Insights,
Beverly
Hills,
CA, USA,
3Amgen
Europe,
Zug,
Switzerland,
4Insitut
Gustave
Roussy,
Villejuif
Cedex,
France
|
|
PCN25
|
TREATMENT
OF
ACTINIC
KERATOSIS
(AK) AND
BASAL
CELL
CARCINOMA
(BCC)
WITH
METVIX®
(MAL-PDT)
IN REAL
LIFE
PRACTICE:
A COST
OF
ILLNESS
AND
MODEL
VALIDATION
STUDY
|
|
|
Caekelbergh
K,
Annemans
L |
|
|
IMS
Health
Economics
and
Outcomes
Research
(HEOR),
Brussels,
Belgium
|
|
PCN26
|
PHARMACOECONOMIC
ANALYSIS
IN SPAIN
OF
THERAPY
WITH
ERLOTINIB,
DOCETAXEL,
PEMETREXED
OR BEST
SUPPORTIVE
CARE IN
PATIENTS
WITH
ADVANCED
NON-SMALL
CELL
LUNG
CANCER
WHO HAVE
FAILED
PREVIOUS
CHEMOTHERAPY
REGIMENS
|
|
|
Rubio
Terres C1,
Alvarez
Sanz C2,
Marlene
Gylmark
GM3 |
|
|
1Hero
Consulting,
Madrid,
Spain,
2Roche
Farma,
Madrid,
Spain,
3Hoffman-La
Roche
Inc,
Basel,
Switzerland
|
|
PCN27
|
COST-EFFECTIVENESS
AND
COST-UTILITY
OF
FENTANYL
TTS
(DUROGESIC®
25, 50)
VS.
SR/IR
ORAL
MORPHINES
IN THE
MANAGEMENT
OF
CHRONIC
CANCER
PAIN
|
|
|
Estevez-Carrizo
FE |
|
|
University of Montevideo,
Uruguay,
Montevideo,
Uruguay
|
|
PCN28
|
SHOULD
FOTEMUSTINE
BE USED
AS THE
FIRST
LINE
TREATMENT
|
|
|
Faluta T,
Czech M,
Pachocki
R |
|
|
Servier
Polska,
Warsaw,
Poland
|
|
PCN29
|
ECONOMIC
ADVANTAGES
AND
TIMESAVING
OF USING
OXALIPLATIN
CONCENTRATED
SOLUTION
VERSUS
OXALIPLATIN
LYOPHILISED
POWDER
FOR
INFUSION
|
|
|
Favier B1,
Spath HM2,
Anhoury
P3,
Pacull A3 |
|
|
1Centre
Leon
Berard,
Lyon,
France,
2GRESAC,
Lyon,
France,
3IMS
Health
Consulting
&
Services,
Puteaux,
France
|
|
|
|
PCN30
|
ECONOMIC
EVALUATION
OF
FOLFOX4
VERSUS
FOLFOX7
WITH
OXALIPLATIN
STOP-AND-GO
IN
ADVANCED
COLORECTAL
CANCER
PATIENTS
|
|
|
Tilleul
P1, Jasso Mosqueda G2, Trancart A2,
Joly AC1,
Tournigand
C1,
Maindrault-Goebel
F1,
Le Pen C2,
De
Gramont
A1 |
|
|
1Saint-Antoine
Hospital,
Paris,
France,
2Aremis-aegisnet,
Neuilly
sur
Seine,
France
|
|
PCN31
|
A COST
MINIMISATION
ANALYSIS
OF
NAVELBINE-CISPLATIN
VERSUS
GEMCITABINE-CISPLATIN
IN
ADVANCED
NON-SMALL
CELL
LUNG
CANCER
IN
POLAND
|
|
|
Skowron
A,
Polak S,
Brandys
J |
|
|
Jagiellonian University, Cracow, Malopolska, Poland |
|
PCN32
|
COST-MINIMIZATION
ANALYSIS
OF ORAL
VS. IV
FLUDARABINE
FOR THE
TREATMENT
OF
B-CELL
CHRONIC
LYMPHOCYTIC
LEUKEMIA
(B-CLL)
IN
BRAZIL
|
|
|
Araujo G1, Fonseca M1, Bigni R2 |
|
|
1Axia.Bio
Consulting,
São
Paulo,
Brazil,
2INCA,
Rio de
Janeiro,
Brazil
|
|
PCN33
|
A
COST-CONSEQUENCE
ANALYSIS
OF
DARBEPOETIN
ALFA
ADMINISTERED
EVERY 3
WEEKS
(Q3W_DA)
COMPARED
TO
WEEKLY
EPOETIN
ALFA
(QW_EA)
OR
EPOETIN
BETA
(QW_EB)
IN
PATIENTS
WITH
CHEMOTHERAPY-INDUCED
ANEMIA
(CIA): A
RETROSPECTIVE
STUDY
|
|
|
Van
Bellinghen
LA1,
Demarteau
N1,
Annemans
L1,
Bracco A2 |
|
|
1IMS
HEOR,
Brussels,
Belgium,
2Amgen
(Europe)
GmbH,
Zug,
Switzerland
|
|
PCN34
|
EFFECT
OF
METASTASIS
LOCALIZATION
ON
SYMPTOMS
AND
ASSISTANCE
COSTS IN
ADVANCED
NSCLC
PATIENTS.
FURTHER
EVIDENCE
FROM THE
HABIT
STUDY.
|
|
|
Negrini
C1, Falcone A2 |
|
|
1Pbe
consulting,
Milano,
Italy,
2AstraZeneca,
Basiglio,
MI,
Italy
|
|
PCN35
|
BURDEN
OF
ILLNESS
OF RENAL
CELL
CARCINOMA
IN SPAIN
|
|
|
Maroto P1,
Villavicencio
H2,
Piñol C3,
Urruticoechea
L4 |
|
|
1Hospital
de la
Santa
Creu i
Sant
| | |
